Last reviewed · How we verify
Exenatide placebo (saline) — Competitive Intelligence Brief
marketed
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Exenatide placebo (saline) (Exenatide placebo (saline)) — GlaxoSmithKline. This is a placebo (saline injection) with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Exenatide placebo (saline) TARGET | Exenatide placebo (saline) | GlaxoSmithKline | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Exenatide placebo (saline) CI watch — RSS
- Exenatide placebo (saline) CI watch — Atom
- Exenatide placebo (saline) CI watch — JSON
- Exenatide placebo (saline) alone — RSS
Cite this brief
Drug Landscape (2026). Exenatide placebo (saline) — Competitive Intelligence Brief. https://druglandscape.com/ci/exenatide-placebo-saline. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab